The clinical presentation of mesothelioma is rather insidious and a very late diagnosis is made in most patients due to the nonspecific nature of complaints [1] [2]. It is established that up to 4 months pass from the onset of symptoms before the tumor is recognized [3], which significantly reduces survival rates. Mesotheliomas are much more likely to occur in men, primarily due to its association with occupational exposure to asbestos and other known carcinogens (the male-to-female ratio is established at 5:1) [2] [4]. The clinical presentation depends on the location of the tumor, with the two main locations being the pleura (the most common) and the peritoneum [1] [2] [3] [4]. In the majority of cases suffering from pleural mesothelioma, a nonproductive cough that is often accompanied by dyspnea, fatigue, diaphoresis, and focal chest pain in some people are notable complaints [1] [2] [5]. Rarely, scoliosis toward the ipsilateral side or splinting may develop due to the expansive nature of the tumor [1]. Conversely, abdominal pain, swelling, anorexia, profound losses in body weight, as well as ascites are manifestations of peritoneal mesothelioma [3]. In some patients, the diagnosis is made incidentally [3].

The diagnostic workup should start with a meticulous clinical assessment. A detailed history must cover the onset of symptoms and their progression, as well as occupational details and whether exposure to asbestos or other harmful chemicals exists. During the physical examination, dullness on percussion due to a pleural effusion or diminished breathing sounds may be detected in the case of pleural mesotheliomas [1], in which case imaging studies need to be employed. Although plain radiography is a useful first-line study for the evaluation of the chest, more advanced studies, such as computed tomography (CT), magnetic resonance imaging (MRI), endoscopic ultrasonography (EUS), mediastinoscopy, laparoscopy, and positron emission tomography (PET) are recommended, primarily because they are able to determine the stage and aid in designing the optimal therapeutic strategy [1] [2] [3] [6]. To make a definite diagnosis, however, a sample of the tumor must be obtained for a histopathological examination. Because pleural cytology is not useful in the case of mesothelioma, fine-needle aspiration biopsy (FNAB), often guided by CT, or video-assisted thoracoscopy (which shows superior results compared to FNAB) are viable techniques that are used in practice [1] [2]. Immunohistochemical staining should include calretinin, as it carries a sensitivity rate of 95% and a specificity rate of 87% [2]. Other important markers are cytokeratin, mesothelin, and D2-40 [1] [2] [7].

Treatment for mesothelioma depends on the stage of the disease, the patient's overall health, and the specific characteristics of the cancer. Options may include surgery to remove the tumor, chemotherapy to kill cancer cells, and radiation therapy to target affected areas. In some cases, a combination of these treatments is used. Emerging therapies, such as immunotherapy, are also being explored. Treatment aims to control symptoms, improve quality of life, and extend survival.

The prognosis for mesothelioma is generally poor, largely due to its aggressive nature and late diagnosis. The average survival time after diagnosis ranges from 12 to 21 months, depending on various factors such as the stage at diagnosis and the patient's response to treatment. Early detection and advances in treatment are improving outcomes, but mesothelioma remains a challenging disease to treat effectively.

The primary cause of mesothelioma is exposure to asbestos, a naturally occurring mineral once widely used in construction, insulation, and various industries. Asbestos fibers, when inhaled or ingested, can become lodged in the mesothelium, leading to inflammation and, over time, cancer. Other potential risk factors include radiation exposure and genetic predisposition, though these are less common.

Mesothelioma is a rare cancer, with approximately 3,000 new cases diagnosed annually in the United States. It predominantly affects older adults, with the majority of cases occurring in individuals aged 65 and older. Men are more frequently diagnosed than women, likely due to occupational exposure to asbestos. The incidence of mesothelioma has been declining in recent years, reflecting reduced asbestos use and improved safety regulations.

Mesothelioma develops when asbestos fibers are inhaled or ingested and become embedded in the mesothelial cells. These fibers cause chronic inflammation and genetic damage, leading to uncontrolled cell growth and tumor formation. The cancer can spread locally to nearby tissues and organs or metastasize to distant sites. The latency period between asbestos exposure and disease onset can be several decades, complicating early detection.

Preventing mesothelioma primarily involves minimizing exposure to asbestos. This includes following safety regulations in workplaces where asbestos is present, using protective equipment, and ensuring proper removal and disposal of asbestos-containing materials. Public awareness and education about the risks of asbestos are also crucial in preventing exposure and reducing the incidence of mesothelioma.

Mesothelioma is a rare and aggressive cancer linked to asbestos exposure, affecting the lining of the lungs, abdomen, or other organs. It presents with non-specific symptoms, making early diagnosis difficult. Treatment options include surgery, chemotherapy, and radiation, but the prognosis remains poor. Prevention focuses on reducing asbestos exposure and adhering to safety guidelines.

If you or a loved one has been diagnosed with mesothelioma, it's important to understand the disease and its implications. Mesothelioma is a cancer that affects the lining of the lungs or abdomen, often caused by exposure to asbestos. Symptoms can include chest pain, shortness of breath, and abdominal swelling. While treatment options are available, early detection is key to improving outcomes. Reducing exposure to asbestos is the best way to prevent this disease.

1. Mott FE. Mesothelioma: A Review. Ochsner J. 2012;12(1):70-79.
2. Porpodis K, Zarogoulidis P, Boutsikou E, et al. Malignant pleural mesothelioma: current and future perspectives. J Thorac Dis. 2013;5(Suppl 4): S397-S406.
3. Bridda A, Padoan I, Mencarelli R, Frego M. Peritoneal Mesothelioma: A Review. Medscape General Medicine. 2007;9(2):32.
4. Nasreen N, Khodayari N, Mohammed KA. Advances in malignant pleural mesothelioma therapy: targeting EphA2 a novel approach. Am J Cancer Res. 2012;2:222-234.
5. Muers MF, Stephens RJ, Fisher P, et al. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet 2008;371:1685-1694.
6. Pickhardt PJ, Bhalla S. Primary neoplasms of peritoneal and sub-peritoneal origin: CT findings. Radiographics. 2005;25:983–995.
7. Husain AN, Colby TV, Ordóñez NG, et al. Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med. 2009;133(8):1317–1331.